Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors
Cai, Z.-W., Wei, D., Schroeder, G.M., Cornelius, L.A., Kim, K., Chen, X.-T., Schmidt, R.J., Williams, D.K., Tokarski, J.S., An, Y., Sack, J.S., Manne, V., Kamath, A., Zhang, Y., Marathe, P., Hunt, J.T., Lombardo, L.J., Fargnoli, J., Borzilleri, R.M.(2008) Bioorg Med Chem Lett 18: 3224-3229
- PubMed: 18479916 
- DOI: https://doi.org/10.1016/j.bmcl.2008.04.047
- Primary Citation of Related Structures:  
3CTH, 3CTJ - PubMed Abstract: 
A series of acylurea analogs derived from pyrrolopyridine and aminopyridine scaffolds were identified as potent inhibitors of Met kinase activity. The SAR at various positions of the two kinase scaffolds was investigated. These studies led to the discovery of compounds 3b and 20b, which demonstrated favorable pharmacokinetic properties in mice and significant antitumor activity in a human gastric carcinoma xenograft model.
Organizational Affiliation: 
Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543-4000, USA. zhenwei.cai@bms.com